Onconova Therapeutics (NASDAQ:ONTX – Get Rating) will release its earnings data after the market closes on Wednesday, May 11th. Analysts expect Onconova Therapeutics to post earnings of ($0.18) per share for the quarter.
Onconova Therapeutics (NASDAQ:ONTX – Get Rating) last released its quarterly earnings data on Thursday, March 17th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.08 million. Onconova Therapeutics had a negative net margin of 7,151.77% and a negative return on equity of 38.96%. During the same quarter in the prior year, the business posted ($0.45) earnings per share. On average, analysts expect Onconova Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ:ONTX opened at $1.41 on Thursday. The firm has a 50 day moving average of $1.65 and a 200 day moving average of $2.28. The company has a market capitalization of $29.47 million, a price-to-earnings ratio of -1.48 and a beta of 1.80. Onconova Therapeutics has a 52 week low of $1.36 and a 52 week high of $16.50.
Several research analysts have recently commented on the company. StockNews.com began coverage on Onconova Therapeutics in a research report on Monday. They issued a “hold” rating for the company. LADENBURG THALM/SH SH started coverage on shares of Onconova Therapeutics in a report on Tuesday, March 1st. They issued a “buy” rating and a $7.00 target price for the company. Finally, Zacks Investment Research raised shares of Onconova Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Wednesday, March 23rd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $8.00.
Onconova Therapeutics Company Profile (Get Rating)
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Onconova Therapeutics (ONTX)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.